NSAIDs/Acetaminophen

In the absence of direct evidence, expert consensus supports the use of nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen for symptomatic relief in ankle osteoarthritis (OA) as part of a multimodal management plan, with consideration of patient-specific safety risks.

Clinical Implications 

Based on expert consensus: 

• NSAIDs or acetaminophen can be administered to patients with symptomatic ankle OA to improve patient-reported outcomes. 
• Their effect on OA progression or need for invasive intervention is unknown. 
• Choice of therapy should consider patient comorbidities, contraindications, and potential adverse effects (e.g., gastrointestinal, renal, cardiovascular for NSAIDs; hepatotoxicity for acetaminophen). 
• Topical NSAIDs may be preferred in patients at higher risk of systemic adverse events. 
• These medications should be integrated into a multimodal management plan, including activity modification, bracing, and physical therapy. 

Limitations 

• No primary studies specifically evaluated NSAIDs or acetaminophen in ankle OA. 
• Recommendations rely solely on expert consensus and extrapolation from other joints (e.g., knee or hip OA). 
• Long-term effectiveness, impact on structural disease progression, and ability to delay invasive intervention remain unknown. 

Future Research 

• Conduct randomized controlled trials or high-quality observational studies evaluating NSAIDs and acetaminophen in ankle OA. 
• Assess short- and long-term effects on patient-reported outcomes, OA progression, and need for surgical intervention. 
• Compare oral versus topical formulations regarding efficacy, safety, and tolerability. 
• Evaluate integration with multimodal management strategies and cost-effectiveness. 

 Benefits and Harms: 

• Potential benefits: Symptom relief, improved function, and quality of life. 
• Potential harms: NSAIDs carry gastrointestinal, renal, and cardiovascular risks; acetaminophen carries hepatotoxicity risk, particularly at high doses or with chronic use. 

Cost-Effectiveness and Resource Utilization: 

• NSAIDs and acetaminophen are inexpensive and widely available. 
• Long-term cost-effectiveness and impact on delaying invasive interventions remain unknown. 

Future Research: 

• Prospective trials and health economic analyses evaluating effectiveness, safety, and cost implications are needed. 
• Studies should examine integration of pharmacologic treatment within multimodal management strategies.